<html>
<head>PUBMED IDs for HOM-MEL-40</head>
<body bgcolor='#C5F0F2'><h1>HOM-MEL-40</h1><a href='https://pubmed.ncbi.nlm.nih.gov/8840996/'>The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40.</a> October 15  1996<br><a href='https://pubmed.ncbi.nlm.nih.gov/9050879/'>A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.</a> March 4  1997<br><a href='https://pubmed.ncbi.nlm.nih.gov/9378559/'>SSX: a multigene family with several members transcribed in normal testis and human cancer.</a> November 5  1997<br><a href='https://pubmed.ncbi.nlm.nih.gov/9560255/'>Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens.</a> June 6  1998<br><a href='https://pubmed.ncbi.nlm.nih.gov/9639388/'>Expression of SSX genes in human tumors.</a> June 25  1998<br><a href='https://pubmed.ncbi.nlm.nih.gov/10704737/'>Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9.</a> March 8  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/11051238/'>Expression of cancer testis genes in human brain tumors.</a> October 29  2000<br><a href='https://pubmed.ncbi.nlm.nih.gov/12681366/'>Expression of serologically identified tumor antigens in acute leukemias.</a> April 12  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/12747756/'>Expression of cancer-testis genes in human hepatocellular carcinomas.</a> May 16  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/14677925/'>Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.</a> December 18  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/15382048/'>Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.</a> September 24  2004<br><a href='https://pubmed.ncbi.nlm.nih.gov/21630107/'>A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.</a> December 13  2011<br></body></html>
